Depletion of conventional CD4⁺ T cells is required for robust priming and dissemination of tumor antigen-specific CD8⁺ T cells in the setting of anti-CD4 therapy.

ABSTRACT:

Background

Overcoming immune suppression is a major barrier to eliciting potent CD8⁺ T cell responses against cancer. Treatment with anti-CD4 monoclonal antibody is an effective means for eliminating CD4⁺Foxp3⁺ regulatory (Treg) cells in preclinical models and has also demonstrated efficacy in early clinical trials. However, the underlying basis for treatment efficacy, more specifically the implications of codepleting other CD4-expressing cell compartments in tumor-bearing hosts, is not well understood.

Methods

Tumor-bearing mice were treated with anti-CD4 versus other therapies that preserve helper T cell function, and the priming, tissue distribution, and maintenance of tumor antigen-specific CD8 T cells were assessed. Antibody blockade and

SUBMITTER: Ramirez DE 

PROVIDER: S-EPMC11552015 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature